Tumor-suppressor p53: Implications for tumor development and prognosis

被引：241

作者：

Kirsch, DG ^{[1
]}

Kastan, MB ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 09期

关键词：

D O I：

10.1200/JCO.1998.16.9.3158

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The p53 protein plays a central role in modulating cellular responses to cytotoxic stresses by contributing to both cell-cycle arrest and programmed cell death. Loss of p53 function during tumorigenesis can lead to inappropriate cell growth, increased cell survival, and genetic instability, p53 gene mutations occur in approximately half of all malignancies from a wide range of human rumors. In some tumor types, these p53 mutations are associated with poor prognosis and treatment failure, Based on these insights, new approaches are being developed to prevent diagnose, and treat cancer. J Clin Oncol 16:3158-3168. (C) 1998 by American Society of Clinical Oncology.

引用

页码：3158 / 3168

页数：11

共 130 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2] Inhibition of Bax channel-forming activity by Bcl-2 [J].

Antonsson, B ;

Conti, F ;

Ciavatta, A ;

Montessuit, S ;

Lewis, S ;

Martinou, I ;

Bernasconi, L ;

Bernard, A ;

Mermod, JJ ;

Mazzei, G ;

Maundrell, K ;

Gambale, F ;

Sadoul, R ;

Martinou, JC .

SCIENCE, 1997, 277 (5324) :370-372

[3] SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].

BAKER, SJ ;

MARKOWITZ, S ;

FEARON, ER ;

WILLSON, JKV ;

VOGELSTEIN, B .

SCIENCE, 1990, 249 (4971) :912-915

[4] CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].

BAKER, SJ ;

FEARON, ER ;

NIGRO, JM ;

HAMILTON, SR ;

PREISINGER, AC ;

JESSUP, JM ;

VANTUINEN, P ;

LEDBETTER, DH ;

BARKER, DF ;

NAKAMURA, Y ;

WHITE, R ;

VOGELSTEIN, B .

SCIENCE, 1989, 244 (4901) :217-221

[5] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].

BARAK, Y ;

JUVEN, T ;

HAFFNER, R ;

OREN, M .

EMBO JOURNAL, 1993, 12 (02) :461-468

[6]

BARDEESY N, 1995, CANCER RES, V55, P215

[7] ANAPLASTIC WILMS-TUMOR, A SUBTYPE DISPLAYING POOR-PROGNOSIS, HARBORS P53 GENE-MUTATIONS [J].

BARDEESY, N ;

FALKOFF, D ;

PETRUZZI, MJ ;

NOWAK, N ;

ZABEL, B ;

ADAM, M ;

AGUIAR, MC ;

GRUNDY, P ;

SHOWS, T ;

PELLETIER, J .

NATURE GENETICS, 1994, 7 (01) :91-97

[8] THE EPIDERMAL GROWTH-FACTOR RECEPTOR AS A TARGET FOR THERAPY IN BREAST-CARCINOMA [J].

BASELGA, J ;

MENDELSOHN, J .

BREAST CANCER RESEARCH AND TREATMENT, 1994, 29 (01) :127-138

[9]

BENNETT WP, 1993, CANCER RES, V53, P4817

[10] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].

BERGH, J ;

NORBERG, T ;

SJOGREN, S ;

LINDGREN, A ;

HOLMBERG, L .

NATURE MEDICINE, 1995, 1 (10) :1029-1034

← 1 2 3 4 5 6 7 8 9 10 →